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Results: A significant increase (P < 0.05) in feed consumption, body 
weight gain, relative weights of testis and epididymis and intratesticu-
lar cholesterol level, follicle stimulating hormone (FSH), luteinizing 
hormone (LH), and prolactin was found in rats received dimethoate. 
On the other side, a significant decrease (P < 0.05) in absolute weight 
of testes and epididymis, serum cholesterol and testosterone levels, 
serum acetylcholine esterase (AChE) activity ,total sperm count, 
motility and fertility index was observed compared with the control 
group. Histopathologic results also indicated enlargement of inter-
stitial space, inhibition of spermatogenesis, and variable degrees of 
degenerative changes in the seminiferous tubules up to total cellular 
destruction.
Conclusion: Our results proved that dimethoate, could act as neu-
roendocrine disruptor via inhibition of AChE activity and increase 
of acetylcholine level in brain. This effect might be linked to the 
suppression of the brain’s release of hormones that stimulate the 
gonadotrophic hormones (LH and FSH). So we have to be aware 
that dimethoate has detrimental effects on the male rat reproductive 
system.
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Introduction: The art of herbal healing has very deep roots in 
Bangladeshi culture and folklore. Unani medicines serve as a major 
source of primary health care for Bangladeshi people. The reasons for 
their use range from easy access, affordability, beliefs in traditional 
systems, and long-term safety. Unani medicines have been used to 
treat individuals infected with human immunodeficiency virus (HIV) 
and therefore need scientific validation, a view supported by the herb-
alists.
Patients (or Materials) and Methods: The studies aimed to evaluates 
the in vitro cytotoxicity, immune-modulatory, and anti-HIV activi-
ties of traditional multiple herbal preparations from the herbalists. 
Triphola, Mohasudarshan, Doshomula, Sarasvati, and Hingoshtak 
medicines were supplied by the herbalists.
Results: Changes in adenosine triphosphate and glutathione over 36 
hours were measured using luminometry. Changes in 13 cytokines 
were assayed using an enzyme-linked immunosorbent assay–based 
absorbance assay. Protective effects against HIV killing of metal-
lothionein-IV cells were tested using the cell proliferation kit assay, 
and antiviral activities was measured using an HIV-1 viral load 
assay. Cyclosporine and azidothymidine were used as positive con-
trols. Mohasudarshan, Doshomula, and Sarasvati induced a dose-
dependent toxicity on treated peripheral blood mononuclear cells by 
reducing adenosine triphosphate, and glutathione at high doses (P < 
0.001). These remedial preparations, along with Triphola, showed 
immunomodulatory activities by significantly (P < 0.001) chang-
ing the secretion of pro-inflammatory cytokines. Hingoshtak stimu-
lated the levels of adenosine triphosphate, and glutathione in treated 
peripheral blood mononuclear cells at all doses however this remedial 
did not show any immunomodulatory activities on cytokine secretion 
when compared with control cells. Doshomula, Mohasudarshan, and 
Triphola showed promising anti-HIV activities relative to azidothy-
midine (P < 0.01).
Conclusion: The studies have exposed that some of these traditional 
remedial preparations have at least 1 or all the properties of immu-
nostimulation, immunomodulation otherwise antiretroviral effects. 
Proper scientific studies conducted on these preparations may lead to 
discovery of more effective drugs than in use at present.
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Introduction: Leptospirosis has emerged as a globally spread infec-
tious disease that is caused by spirochete bacteria of the genus 
Leptospira. Xanthones from pericarp of Garcinia mangostana and 
their analogs widely used as medicinal agents against several infec-
tious diseases were examined for inhibitory activity and investigated 
for synergistic effects with antibiotics against Leptospira spp.
Patients (or Materials) and Methods: The minimal inhibitory con-
centrations (MIC) of 5 purified xanthones and 8 xanthone analogs 
were determined against 1 nonpathogenic L biflexa serovar Patoc 
and four pathogenic L. interrogans serovars Bataviae, Autumnalis, 
Javanica, and Saigon by using broth microdilution test. The synergis-
tic effects with penicillin G or ampicillin were evaluated by calculat-
ing the fractional inhibitory concentration (FIC) index.
Results: The 2 xanthones from mangosteen, γ -mangostin and garci-
none C, and the 2 xanthone analogs, 1,3,8-trihydroxyxanthone and 
1,3-dihydroxythioxanthone, showed the highest antileptospiral activ-
ities with the MIC varying from 100 to ≥ 800 µg/mL. Combinations 
of γ -mangostin with penicillin G and 1,3,8-trihydroxyxanthone with 
ampicillin generated synergistic effects at the FIC index of 0.05 to 
0.75 and 0.51 to 0.75, respectively. However, antagonistic activity 
against L interrogans serovar Saigon was observed when combining 
γ -mangostin with penicillin G.
Conclusion: The results demonstrated that the xanthones from G 
magostana and hydroxyxanthone analog inhibited growth of lepto-
spires and there were synergistic effects between these xanthones and 
antibiotics, which could enhance the efficacy of both drugs for the 
treatment of leptospirosis.
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Introduction: Objective: To compare the pharmaceutical quality 
of 7 generic levodopa/benserazide combination products marketed 
in Germany with the original product (Madopar® / Prolopa®). 
Madopar® / Prolopa®is a combination of levodopa (L-Dopa), the 
precursor of dopamine (DA), and benserazide, a dopamine decarbox-
ylase inhibitor (DDCI). It is indicated in the treatmentof Parkinson’s 
disease, dopamine-responsive dystonia, and restless legs syndrome.
Patients (or Materials) and Methods: Madopar®/Prolopa®125 
tablets and capsules were used as reference materials. The generic 
products tested (all 100 mg/25 mg formulations) included 4 tablet 
formulations (ie, Levodopa/Benserazid beta [Betapharm], Levodopa/
Benserazid-CT [CT Arzneimittel], dopadura B [Mylan dura], and 
Levodopa/Benserazid ratiopharm [ratiopharm]) and 3 capsulated 
Poster Presentation Abstracts
2013 e95
formulations (ie, Levopar capsules [Hexal], Levodopa comp. B 
STADA [STADApharm] and Levobens-Teva capsules [Teva]). Shape, 
color, appearance, and hardness (tablets) or surface, color, imprint, 
and content (capsules); mass (tablets) or fill-mass (capsules); content, 
degradation products, other unspecified impurities, disintegration 
time and dissolution after 30 minutes were assessed by standard phys-
ical and chemical laboratory tests along the original specifications.
Results: For all 7 generic products, at least 1 of the tested parameters 
fell outside the Madopar®/Prolopa® “shelf-life” specifications for 
the reference. Content requirements were unmet by 2 tablet formu-
lations for L-Dopa (specs: 100 mg ± 5%; test results: –5.6% and 
–7.6%) and for benserazide (specs: 28.5 mg ± 5%; –6.6% and 8.4%). 
Average mass (specs: 275 mg ±3%) was not reached for 2 tablet 
formulations (3.3%), and average fill mass (specs: 150 mg ±5%) was 
not reached for 3 capsule formulations (48.2%, 99.1%, 99.3%). The 
content of 1 capsule was brown (specs: light-beige). The quantity of 
2 benserazide degradation products (Ro 04-1419 and Ro 08-1 580; 
specs: max. 0.49%) was out of limits (0.62%) in 1 of the capsulated 
formulations.
Conclusion: All 7 analyzed generic L-Dopa/benserazide products 
exhibited at least 1 deviation compared with the shelf-life specifica-
tions of Madopar®/Prolopa®125. Deviations for the active ingredi-
ents ranged from 8.4% (benserazide) to –7.6% (L-Dopa) in 2 tablet 
products, which may result in clinical consequences for long-term 
administration. Furthermore, 2 of the degradation products were 
measured in excess of 26.5% above specification standards, posing a 
potential safety concern for treated patients. These results should lead 
to caution when prescribing a generic of Madopar®/Prolopa®, and 
also invite further investigations of a more comprehensive approach, 
from both pharmaceutical and clinical perspectives.
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Introduction: Although no clinically relevant resistance to the only 
schistosomicidal drug praziquantel (PZQ) has been described to date, 
development of drug resistance remains a growing threat. Calotropis 
(C.) procera, Ficus (F.) elastic, and Zingiber (Z.) officinale are well-
known medicinal plants and have been traditionally used for many 
diseases.The present work aimed to evaluate the antischistosomal 
activity of these plant extracts against Schistosoma (S.) mansoni.
Patients (or Materials) and Methods: Male mice exposed to 80 ±10 
cercariae/mouse were divided into 2 batches. The first was divided 
into 5 groups; (I) infected untreated, while groups from (II–V) were 
treated orally (500 mg/kg for 3 consecutive days) by aqueous stem 
latex and flowers of C procera, latex of F elastica and ether extract of 
Z officinale, respectively. The second batch was divided into 4 com-
parable groups (except Z officinale–treated group) similarly treated 
as the first batch in addition to the antacid ranitidine (30 mg/kg) 1 
hour before extract administration. Safety, worm recovery, tissues 
egg load, and oogram pattern were assessed.
Results: Results indicate that C procera latex and flower extracts 
are toxic even in small doses before washing off toxic rubber. 
Z officinale extract produced numerical insignificant decrease 
(7.26%) in S mansoni worms. When toxic rubber was washed off 
and the antacid ranitidine used, C procera (stem latex and flowers) 
and F elastica latex extracts revealed significant antischistosomal 
worm reductions by 45.31%, 53.7%, and 16.71%, respectively. 
Moreover, C procera extracts produced significant reductions in 
tissue egg load (≈ 34%–38.5%) and positively affect the oogram 
pattern.
Conclusion: The present study may be useful to supplement informa-
tion with regard to C procera and F elastica antischistosomal activity 
and provided a basis for subsequent experimental and clinical trials.
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Introduction: Dyes containing an azo (N = N) group are widely 
used in the food, pharmaceutical, cosmetic, and textile industries to 
provide color to products. Reports on the potential carcinogenicity 
of specific azo dyes, like Sudan I, has resulted in it being banned from 
use as a food additive. The association of the azo dyes, Tartrazine and 
Sunset Yellow, with the attention-deficit/ hyperactivity syndrome has 
further vilified azo dyes and focused scientific interest on its potential 
harmful effects. In an attempt to improve understanding of the azo 
dyes and in a search for new lead compounds for cancer drug devel-
opment, we have investigated the effects of a panel of 24 azo dyes on 
the survival of cancer cell lines.
Patients (or Materials) and Methods: A T-cell leukemic cell line 
(Jurkat) and a breast cancer cell line (MCF7) was maintained asepti-
cally in culture according to standard procedures. Cell were exposed 
to azo dyes, and their effects on cell growth and viability was deter-
mined by [3H]-thymidine incorporation into DNA. Labeled thymi-
dine incorporation into DNA was measured by precipitating DNA 
on glass fiber filtermats followed by liquid scintillation counting. Log 
dose-response curves were then constructed using the Graph-Pad 
Prizm software package.
Results: Four of the 20 compounds inhibited the proliferation of 
both Jurkat and MCF7 cells with IC50 values ranging between of 28 
and 82 micromoles. MCF7 cells were inhibited by Eriochrome Blue 
Black B and Eriochrome Black T with IC50 values of 28.43 (1.13) 
and 37.22 (4.6) µM, respectively. Jurkat cells were most sensitive to 
Eriochrome Black T with an IC50 value of 38.69 (2.26) µm compared 
with Eriochrome Blue Black with an IC50 value of 79.95 (1.01). 
Furthermore, Palatine Chrome Black 6BN and 4-phenylazophenol 
inhibited Jurkat cells with IC50 values of 82.04 (1.02) and 72.61 
(1.03) µM, respectively. These data support previous reports regard-
ing the anticancer properties of Eriochrome Black T.
Conclusion: This preliminary study identified 4 azo dyes whose 
structures can serve as lead compounds for new cancer drug devel-
opment. Further studies will investigate the effects of azo dyes on cell 
lines derived from other cancers and determine the potential of the 
active dyes to induce apoptosis.
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